Analyze Diet
Emerging infectious diseases2021; 27(11); 2761-2767; doi: 10.3201/eid2711.211449

Effectiveness of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in Outbreak among Horse Racetrack Workers, California, USA.

Abstract: The Abbott BinaxNOW rapid antigen test is cheaper and faster than real-time reverse transcription PCR (rRT-PCR) for detecting severe acute respiratory syndrome coronavirus 2. We compared BinaxNOW with rRT-PCR in 769 paired specimens from 342 persons during a coronavirus disease outbreak among horse racetrack workers in California, USA. We found positive percent agreement was 43.3% (95% CI 34.6%-52.4%), negative percent agreement 100% (95% CI 99.4%-100%), positive predictive value 100% (95% CI 93.5%-100%), and negative predictive value 89.9% (95% CI 87.5%-92.0%). Among 127 rRT-PCR-positive specimens, the 55 with paired BinaxNOW-positive results had a lower mean cycle threshold than the 72 with paired BinaxNOW-negative results (17.8 vs. 28.5; p<0.001). Of 100 specimens with cycle threshold <30, a total of 51 resulted in positive virus isolation; 45 (88.2%) of those were BinaxNOW-positive. Our comparison supports immediate isolation for BinaxNOW-positive persons and confirmatory testing for negative persons.
Publication Date: 2021-09-01 PubMed ID: 34469287PubMed Central: PMC8544964DOI: 10.3201/eid2711.211449Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study examines the effectiveness of the Abbott BinaxNOW rapid antigen test in detecting SARS-CoV-2 as compared to a traditional RT-PCR test during a Covid-19 outbreak among horse racetrack workers in California. The findings suggest that while the antigen test was successful in quickly identifying those with high viral loads, it was less effective at detecting cases with lower viral amounts.

Research Objectives

  • The primary aim of the study was to evaluate the Abbott BinaxNOW rapid antigen test’s capacity to detect SARS-CoV-2.
  • The researchers compared the BinaxNOW results with those obtained from a real-time reverse transcription PCR (rRT-PCR), often referred to as the gold standard of Covid-19 diagnostic tests.

Methodology

  • The researchers collected 769 paired specimens from 342 individuals during a Covid-19 outbreak among horse racetrack workers in California, USA. These samples were subjected to both BinaxNOW and rRT-PCR testing for comparison.

Findings

  • The Abbott BinaxNOW test showed a positive percent agreement of 43.3%, indicating its ability to accurately detect positive cases was substantially lower than rRT-PCR.
  • Negative percent agreement was found to be 100%, suggesting the rapid test was able to correctly identify all negative cases, as per the rRT-PCR results.
  • The positive predictive value was also 100%, meaning all the subjects that tested positive with BinaxNOW were indeed infected with SARS-CoV-2, showing no false positives occurred.
  • The negative predictive value was lower, at 89.9%, implying that some subjects who tested negative with BinaxNOW were actually infected.
  • Out of 127 rRT-PCR-positive specimens, BinaxNOW detected only 55 cases. These 55 cases had a lower mean cycle threshold than the undetected 72, indicating the antigen test is likely more sensitive to higher viral loads.
  • Out of 100 specimens with a cycle threshold of less than 30, 51 were able to result in virus isolation. Among these, 45 (or 88.2%) were detected as positive by the BinaxNOW test.

Conclusion

  • The results of this study suggest that the BinaxNOW test is most effective in identifying people with high viral loads and should be used to support immediate isolation of positive individuals.
  • However, due to its lower sensitivity in detecting cases with lower viral loads, negative results from the BinaxNOW test should be confirmed with a follow-up rRT-PCR test, to safeguard against potential false negatives in the context of community transmission.

Cite This Article

APA
Surasi K, Cummings KJ, Hanson C, Morris MK, Salas M, Seftel D, Ortiz L, Thilakaratne R, Stainken C, Wadford DA. (2021). Effectiveness of Abbott BinaxNOW Rapid Antigen Test for Detection of SARS-CoV-2 Infections in Outbreak among Horse Racetrack Workers, California, USA. Emerg Infect Dis, 27(11), 2761-2767. https://doi.org/10.3201/eid2711.211449

Publication

ISSN: 1080-6059
NlmUniqueID: 9508155
Country: United States
Language: English
Volume: 27
Issue: 11
Pages: 2761-2767

Researcher Affiliations

Surasi, Krishna
    Cummings, Kristin J
      Hanson, Carl
        Morris, Mary Kate
          Salas, Maria
            Seftel, David
              Ortiz, Liza
                Thilakaratne, Ruwan
                  Stainken, Cameron
                    Wadford, Debra A

                      MeSH Terms

                      • Animals
                      • Antigens, Viral
                      • COVID-19
                      • California / epidemiology
                      • Disease Outbreaks
                      • Horses
                      • Humans
                      • SARS-CoV-2
                      • Sensitivity and Specificity

                      References

                      This article includes 16 references
                      1. Food and Drug Administration. BinaxNOW COVID-19 Ag card (PN 195–000)—instructions for use. 2020 Dec.
                      2. Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. 2020 Dec 5.
                      3. James AE, Gulley T, Kothari A, Holder K, Garner K, Patil N. Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees.. Infect Control Hosp Epidemiol 2022 Jan;43(1):99-101.
                        pmc: PMC7870908pubmed: 33487197doi: 10.1017/ice.2021.20google scholar: lookup
                      4. Okoye NC, Barker AP, Curtis K, Orlandi RR, Snavely EA, Wright C, Hanson KE, Pearson LN. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting.. J Clin Microbiol 2021 Mar 19;59(4).
                        doi: 10.1128/JCM.03282-20pmc: PMC8092740pubmed: 33509809google scholar: lookup
                      5. Pilarowski G, Lebel P, Sunshine S, Liu J, Crawford E, Marquez C, Rubio L, Chamie G, Martinez J, Peng J, Black D, Wu W, Pak J, Laurie MT, Jones D, Miller S, Jacobo J, Rojas S, Rojas S, Nakamura R, Tulier-Laiwa V, Petersen M, Havlir DV, DeRisi J. Performance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco.. J Infect Dis 2021 Apr 8;223(7):1139-1144.
                        doi: 10.1093/infdis/jiaa802pmc: PMC7799021pubmed: 33394052google scholar: lookup
                      6. Pilarowski G, Marquez C, Rubio L, Peng J, Martinez J, Black D, Chamie G, Jones D, Jacobo J, Tulier-Laiwa V, Rojas S, Rojas S, Cox C, Nakamura R, Petersen M, DeRisi J, Havlir DV. Field Performance and Public Health Response Using the BinaxNOWTM Rapid Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Assay During Community-Based Testing.. Clin Infect Dis 2021 Nov 2;73(9):e3098-e3101.
                        doi: 10.1093/cid/ciaa1890pmc: PMC7799223pubmed: 33367619google scholar: lookup
                      7. Pollock NR, Jacobs JR, Tran K, Cranston AE, Smith S, O'Kane CY, Roady TJ, Moran A, Scarry A, Carroll M, Volinsky L, Perez G, Patel P, Gabriel S, Lennon NJ, Madoff LC, Brown C, Smole SC. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts.. J Clin Microbiol 2021 Apr 20;59(5).
                        doi: 10.1128/JCM.00083-21pmc: PMC8091851pubmed: 33622768google scholar: lookup
                      8. Prince-Guerra JL, Almendares O, Nolen LD, Gunn JKL, Dale AP, Buono SA, Deutsch-Feldman M, Suppiah S, Hao L, Zeng Y, Stevens VA, Knipe K, Pompey J, Atherstone C, Bui DP, Powell T, Tamin A, Harcourt JL, Shewmaker PL, Medrzycki M, Wong P, Jain S, Tejada-Strop A, Rogers S, Emery B, Wang H, Petway M, Bohannon C, Folster JM, MacNeil A, Salerno R, Kuhnert-Tallman W, Tate JE, Thornburg NJ, Kirking HL, Sheiban K, Kudrna J, Cullen T, Komatsu KK, Villanueva JM, Rose DA, Neatherlin JC, Anderson M, Rota PA, Honein MA, Bower WA. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.. MMWR Morb Mortal Wkly Rep 2021 Jan 22;70(3):100-105.
                        doi: 10.15585/mmwr.mm7003e3pmc: PMC7821766pubmed: 33476316google scholar: lookup
                      9. Carlsten C, Gulati M, Hines S, Rose C, Scott K, Tarlo SM, Torén K, Sood A, de la Hoz RE. COVID-19 as an occupational disease.. Am J Ind Med 2021 Apr;64(4):227-237.
                        doi: 10.1002/ajim.23222pmc: PMC8014565pubmed: 33491195google scholar: lookup
                      10. Waltenburg MA, Victoroff T, Rose CE, Butterfield M, Jervis RH, Fedak KM, Gabel JA, Feldpausch A, Dunne EM, Austin C, Ahmed FS, Tubach S, Rhea C, Krueger A, Crum DA, Vostok J, Moore MJ, Turabelidze G, Stover D, Donahue M, Edge K, Gutierrez B, Kline KE, Martz N, Rajotte JC, Julian E, Diedhiou A, Radcliffe R, Clayton JL, Ortbahn D, Cummins J, Barbeau B, Murphy J, Darby B, Graff NR, Dostal TKH, Pray IW, Tillman C, Dittrich MM, Burns-Grant G, Lee S, Spieckerman A, Iqbal K, Griffing SM, Lawson A, Mainzer HM, Bealle AE, Edding E, Arnold KE, Rodriguez T, Merkle S, Pettrone K, Schlanger K, LaBar K, Hendricks K, Lasry A, Krishnasamy V, Walke HT, Rose DA, Honein MA. Update: COVID-19 Among Workers in Meat and Poultry Processing Facilities - United States, April-May 2020.. MMWR Morb Mortal Wkly Rep 2020 Jul 10;69(27):887-892.
                        doi: 10.15585/mmwr.mm6927e2pmc: PMC7732361pubmed: 32644986google scholar: lookup
                      11. Dahdouh E, Lázaro-Perona F, Romero-Gómez MP, Mingorance J, García-Rodriguez J. C(t) values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load.. J Infect 2021 Mar;82(3):414-451.
                        doi: 10.1016/j.jinf.2020.10.017pmc: PMC7585367pubmed: 33131699google scholar: lookup
                      12. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.. JAMA 2020 Jun 9;323(22):2249-2251.
                        doi: 10.1001/jama.2020.8259pubmed: 32374370google scholar: lookup
                      13. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment.. N Engl J Med 2020 Nov 26;383(22):e120.
                        doi: 10.1056/NEJMp2025631pubmed: 32997903google scholar: lookup
                      14. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.. Open Forum Infect Dis 2021 Feb;8(2):ofab050.
                        doi: 10.1093/ofid/ofab050pmc: PMC7888564pubmed: 33623808google scholar: lookup
                      15. National Oceanic and Atmospheric Administration. Temperature data from the weather station in Richmond, CA, on the following dates: Nov. 25, 27, 28; Dec. 4, 13, 16, 20, 22. .
                      16. Centers for Disease Control and Prevention. Interim guidance for SARS-CoV-2 testing in non-healthcare workplaces. 2021 Mar 17.

                      Citations

                      This article has been cited 5 times.
                      1. Xie JW, Zheng YW, Wang M, Lin Y, He Y, Lin LR. Nasal swab is a good alternative sample for detecting SARS-CoV-2 with rapid antigen test: A meta-analysis.. Travel Med Infect Dis 2023 Mar-Apr;52:102548.
                        doi: 10.1016/j.tmaid.2023.102548pubmed: 36758806google scholar: lookup
                      2. Konyak BM, Sharma M, Kharia S, Pandey RP, Chang CM. A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies.. Vaccines (Basel) 2022 Sep 5;10(9).
                        doi: 10.3390/vaccines10091468pubmed: 36146546google scholar: lookup
                      3. Nguyen N, Lane B, Lee S, Gorman SL, Wu Y, Li A, Lu H, Elhadad N, Yin M, Meyers K. A mixed methods study evaluating acceptability of a daily COVID-19 testing regimen with a mobile-app connected, at-home, rapid antigen test: Implications for current and future pandemics.. PLoS One 2022;17(8):e0267766.
                        doi: 10.1371/journal.pone.0267766pubmed: 35939422google scholar: lookup
                      4. Kweon OJ, Lee JH, Choi YS, Kim BS, Lim YK, Lee MK, Park JH, Park JY, Kim SH. Positivity of Rapid Antigen Testing for SARS-CoV-2 With Serial Followed-up Nasopharyngeal Swabs in Hospitalized Patients due to COVID-19.. J Korean Med Sci 2022 May 30;37(21):e168.
                        doi: 10.3346/jkms.2022.37.e168pubmed: 35638195google scholar: lookup
                      5. Liu L, Meyers K, Purpura LJ, Nguyen N, Mohri H, Chang JY, Annavajhala MK, Lopez L 3rd, Lee SW, Shah J, Lane B, Cantos A, Tukuru SA, Guo Y, Ford K, Chiu YT, Sheng Z, Choesang T, Castor D, Wang M, Pili C, Van Hoy MN, Wallach A, Horton J, Chen Z, Rosenthal S, McLaren S, Jiang B, Wang F, Lu HH, Uhlemann AC, Ho DD, Yin MT. Development and performance of a point-of-care rapid antigen test for detection of SARS-COV-2 variants.. J Clin Virol Plus 2022 Aug;2(3):100080.
                        doi: 10.1016/j.jcvp.2022.100080pubmed: 35528048google scholar: lookup